393 related articles for article (PubMed ID: 25356988)
1. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer.
Buffen K; Oosting M; Quintin J; Ng A; Kleinnijenhuis J; Kumar V; van de Vosse E; Wijmenga C; van Crevel R; Oosterwijk E; Grotenhuis AJ; Vermeulen SH; Kiemeney LA; van de Veerdonk FL; Chamilos G; Xavier RJ; van der Meer JW; Netea MG; Joosten LA
PLoS Pathog; 2014 Oct; 10(10):e1004485. PubMed ID: 25356988
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in Asian patients.
Zang Z; Lim YK; Chan YH; Raman L; Esuvaranathan K; Chiong E; Mahendran R
Urol Oncol; 2021 Apr; 39(4):238.e1-238.e7. PubMed ID: 33250346
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
Sfakianos JP; Salome B; Daza J; Farkas A; Bhardwaj N; Horowitz A
Urol Oncol; 2021 Feb; 39(2):121-129. PubMed ID: 33262028
[TBL] [Abstract][Full Text] [Related]
4. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
5. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy.
DiPaola RS; Lattime EC
J Urol; 2007 Nov; 178(5):1840-1. PubMed ID: 17868741
[No Abstract] [Full Text] [Related]
8. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
Herr HW; Dalbagni G
BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
[TBL] [Abstract][Full Text] [Related]
9. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
11. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer.
van Puffelen JH; Keating ST; Oosterwijk E; van der Heijden AG; Netea MG; Joosten LAB; Vermeulen SH
Nat Rev Urol; 2020 Sep; 17(9):513-525. PubMed ID: 32678343
[TBL] [Abstract][Full Text] [Related]
12. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
13. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
Kamat AM; Briggman J; Urbauer DL; Svatek R; Nogueras González GM; Anderson R; Grossman HB; Prat F; Dinney CP
Eur Urol; 2016 Feb; 69(2):197-200. PubMed ID: 26119560
[TBL] [Abstract][Full Text] [Related]
14. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
15. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity.
Arts RJW; Moorlag SJCFM; Novakovic B; Li Y; Wang SY; Oosting M; Kumar V; Xavier RJ; Wijmenga C; Joosten LAB; Reusken CBEM; Benn CS; Aaby P; Koopmans MP; Stunnenberg HG; van Crevel R; Netea MG
Cell Host Microbe; 2018 Jan; 23(1):89-100.e5. PubMed ID: 29324233
[TBL] [Abstract][Full Text] [Related]
16. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
19. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
Huang Z; Liu H; Wang Y; Zhang C; Xu T
Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
[TBL] [Abstract][Full Text] [Related]
20. Should intravesical Bacillus Calmette-Guérin be employed in transplant recipients with bladder carcinoma?
Sun HY; Singh N
Transpl Infect Dis; 2010 Aug; 12(4):358-62. PubMed ID: 20412534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
